Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. E. Park, A. Sheth, T. B. Ho, B. P. Madden (London, United Kingdom). Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease. Eur Respir J 2004; 24: Suppl. 48, 4330

Member's Comments

No comment yet.

Related content which might interest you: Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015 Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Bosentan for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2007; 30: 922-927 Year: 2007 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Survival in medically treated chronic thromboembolic pulmonary hypertension patients Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients Source: Eur Respir J, 52 (5) 1800248; 10.1183/13993003.00248-2018 Year: 2018 Survival in patients with chronic thromboembolic pulmonary hypertension in the modern management era Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003 Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia. Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Osteoporosis in patients with idiopathic and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients. Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018 Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 263-271 Year: 2015 Diagnosis of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2017; 26: 160108 Year: 2017